Irene van Heuvel

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial

Walter Taal, Hendrika M. Oosterkamp, Annemiek Walenkamp et al. · The Lancet Oncology · 2014 · 753 citations

Medicine, Oncology, Pharmacotherapy +16

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

Martin J. van den Bent, Brigitta G. Baumert, Sara Erridge et al. · The Lancet · 2017 · 397 citations · Full text

Medicine, Oncology, Pharmacology +17

<i>IDH1</i> mutations in low-grade astrocytomas predict survival but not response to temozolomide

Hendrikus J. Dubbink, Walter Taal, Ronald van Marion et al. · Neurology · 2009 · 187 citations

Medicine, Oncology, Radiation Oncology +14

Successful treatment of low‐grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine

Elize M. Biemond‐ter Stege, Johan M. Kros, Hein G. de Bruin et al. · Cancer · 2005 · 126 citations

Medicine, Oncology, Pharmacology +13

Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas

V. H.J.M. Triebels, Martin Taphoorn, Alba A. Brandes et al. · Neurology · 2004 · 88 citations

Medicine, Oncology, Pharmacology +12